BioLineRx Ltd. (BLRX)

BioLineRx Ltd. ( BLRX ) Q3 2025 Earnings Call November 24, 2025 8:30 AM EST Company Participants Irina Koffler - Managing Director Philip Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Ella Sorani - Chief Development Officer Conference Call Participants Joseph Pantginis - H.C.

- Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers - - Phase 1/2a clinical trial of GLIX1 expected to commence in Q1 2026 - - Management to host conference call today, November 24 th, at 8:30 am EST - TEL AVIV, Israel , Nov. 24, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended September 30, 2025, and provided a corporate update.

Management to Hold Conference Call at 8:30 a.m. EST TEL AVIV, Israel , Nov. 18, 2025 /PRNewswire/ -- BioLineRx Ltd.

Patent covers the use of GLIX1 for treating cancers in which cytidine deaminase (CDA) is not over-expressed (representing over 90% of cancers) Patent further broadens and strengthens GLIX1 patent protection until 2040, with a possible patent-term extension of up to five years TEL AVIV, Israel , Nov. 17, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a key patent, entitled, 'Deoxy-Cytidine or Uridine Derivatives for Use in Cancer Therapies' (Pat.

BioLineRx Ltd. - Special Call Company Participants Irina Koffler - Managing Director Philip Serlin - Chief Executive Officer Ella Sorani - Chief Development Officer Conference Call Participants Joseph Pantginis - H.C.

- GLIX1 restores TET2 activity in cancer, resulting in double stranded DNA breaks in cancer cells only - - FDA IND clearance received for Phase 1/2a study, expected to initiate in Q1 2026 - - Glioblastoma market opportunity estimated to be in excess of $3.8 billion annually across the US and EU5 by 2030 - - BioLineRx affirms its cash runway into the first half of 2027 - - Management to host conference call today, September 29 th, at 8:30 am EDT - TEL AVIV, Israel and OSLO, Norway , Sept. 29, 2025 /PRNewswire/ -- BioLineRx Ltd.

BioLineRx Ltd. (NASDAQ:BLRX ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Irina Koffler - Corporate Participant Mali Zeevi - Chief Financial Officer Philip A.

- Reports continued progress in the evaluation of assets for potential pipeline expansion in the areas of oncology and rare disease; transaction targeted for 2025 -- Provides updated and extended cash runway guidance into H1 2027 -- Management to host conference call today, August 14th, at 8:30 am EDT - TEL AVIV, Israel , Aug. 14, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended June 30, 2025, and provided a corporate update.

Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , Aug. 7, 2025 /PRNewswire/ -- BioLineRx Ltd.

Markets hate uncertainty, which has been the norm in 2025. Tariffs, interest rates, and inflation are driving analysts' expectations.

BioLineRx Ltd's BLRX poster, which includes new data from the single-arm pilot phase of the investigator-initiated, randomized CheMo4METPANC Phase 2 combination trial, will be presented at the 2025 American Society of Clinical Oncology Annual Meeting.

BioLineRx Ltd. (NASDAQ:BLRX ) Q1 2025 Earnings Conference Call May 27, 2025 8:30 AM ET Company Participants Irina Koffler - IR, LifeSci Advisors Philip Serlin - CEO Mali Zeevi - CFO Ella Sorani - Chief Development Officer Conference Call Participants Joe Pantginis - H.C.

- Reports continued progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare disease - - New data from pilot phase of ongoing CheMo4METPANC Phase 2b combination trial of motixafortide in PDAC, sponsored by Columbia University, to be presented at upcoming 2025 ASCO Annual Meeting – - APHEXDA performing well under Ayrmid stewardship - - Management to host conference call today, May 27 th, at 8:30 am EDT - TEL AVIV, Israel , May 27, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended March 31, 2025, and provided a corporate update.

Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , May 20, 2025 /PRNewswire/ -- BioLineRx Ltd.

BioLineRx Ltd. (NASDAQ:BLRX ) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ET Company Participants Irina Koffler - IR, LifeSci Advisors Phil Serlin - CEO Mali Zeevi - CFO Ella Sorani - Chief Development Officer Conference Call Participants Joe Pantginis - HC Wainwright John Vandermosten - Zacks Operator Ladies and gentlemen, thank you for standing by.

- Reports meaningful progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare diseases - - Executed license agreement with Ayrmid Pharma Ltd. for APHEXDA ® (motixafortide) with $10 million upfront payment, up to $87 million in commercial milestones, and high double-digit royalties on net sales - - Completed financings raising combined gross proceeds of $19 million and reduced operating expense run rate by 70%, extending the Company's cash runway through H2 2026 - - Management to host conference call today, March 31 st, at 8:30 am EDT - TEL AVIV, Israel , March 31, 2025 /PRNewswire/ -- BioLineRx Ltd.